Iconovo receives $883,800 grant from the Bill & Melinda Gates Foundation
Funding will develop inhaled therapies using ICOone Nasal in preparation for the next pandemic
Read Moreby John Pinching | Jul 26, 2022 | News | 0
Funding will develop inhaled therapies using ICOone Nasal in preparation for the next pandemic
Read Moreby John Pinching | May 19, 2022 | News | 0
Gifford is supporting the launch with a philanthropic donation of £14.7m
Read Moreby John Pinching | Mar 15, 2022 | News | 0
The initiative will catalyse discovery and early development of antiviral medicines for future pandemics
Read Moreby Lucy Parsons | Apr 22, 2021 | News | 0
Medscape survey finds female doctors reported 30% lower pay compared to male doctors
Read Moreby Selina McKee | Apr 6, 2021 | News | 0
Everyone in England, including those without symptoms, will be able to take a free rapid coronavirus test twice a week
Read Moreby Lucy Parsons | Mar 16, 2021 | News | 0
NHS rolled out new technology at an ‘incredible pace’ during pandemic
Read Moreby Lucy Parsons | Mar 12, 2021 | News | 0
Raises concerns over wellbeing of staff working during pandemic
Read Moreby Selina McKee | Dec 15, 2020 | News | 0
A new report launched by Takeda has found that just 17% of UK adults surveyed felt their perception of pharma had improved based on the industry’s response to COVID-19
Read Moreby Selina McKee | Aug 27, 2020 | News | 0
The interactive tool highlights unprecedented cross-sector collaboration
Read Moreby Selina McKee | Jul 30, 2020 | News | 0
The plan sets out a new a new recruitment, retention and support package
Read Moreby Selina McKee | Jul 24, 2020 | News | 0
New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100 million investment
Read Moreby Selina McKee | Jul 17, 2020 | News | 0
The funds are to help the health service prepare for a winter wave of coronavirus
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
